HC Wainwright Has Strong Forecast for ACRS FY2024 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Investment analysts at HC Wainwright increased their FY2024 earnings estimates for shares of Aclaris Therapeutics in a note issued to investors on Monday, December 23rd. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings per share of ($0.58) for the year, up from their previous forecast of ($0.66). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q4 2024 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.19) EPS and FY2025 earnings at ($0.59) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The business had revenue of $4.35 million for the quarter, compared to the consensus estimate of $8.31 million. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%.

Several other equities research analysts have also recently issued reports on the stock. Piper Sandler upgraded shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $3.00 to $13.00 in a research report on Monday, November 18th. Jefferies Financial Group upgraded shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and lifted their price target for the company from $2.00 to $7.00 in a report on Tuesday, November 19th. Leerink Partnrs upgraded shares of Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 19th. StockNews.com upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 15th. Finally, BTIG Research raised Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price objective on the stock in a research note on Tuesday, November 19th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $11.00.

Aclaris Therapeutics Trading Up 0.3 %

Shares of ACRS opened at $2.90 on Wednesday. The business’s 50 day moving average is $2.76 and its 200 day moving average is $1.75. Aclaris Therapeutics has a 12-month low of $0.86 and a 12-month high of $5.17. The company has a market capitalization of $207.15 million, a PE ratio of -5.58 and a beta of 0.44.

Institutional Trading of Aclaris Therapeutics

Large investors have recently bought and sold shares of the stock. Stonepine Capital Management LLC acquired a new position in shares of Aclaris Therapeutics in the 2nd quarter valued at $2,120,000. Trium Capital LLP purchased a new position in shares of Aclaris Therapeutics during the second quarter worth $2,081,000. BML Capital Management LLC raised its stake in shares of Aclaris Therapeutics by 9.7% during the 3rd quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company’s stock valued at $16,388,000 after buying an additional 1,261,866 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Aclaris Therapeutics in the 3rd quarter valued at about $1,053,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Aclaris Therapeutics by 187.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock worth $382,000 after buying an additional 216,826 shares during the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Insider Transactions at Aclaris Therapeutics

In other Aclaris Therapeutics news, Director Anand Mehra acquired 666,666 shares of the stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average price of $2.25 per share, with a total value of $1,499,998.50. Following the transaction, the director now directly owns 710,030 shares of the company’s stock, valued at $1,597,567.50. This trade represents a 1,537.37 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.40% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.